Chatterjee Tathagata, Ahuja Ankur
Army Hospital (Research and Referral), Delhi Cantt, New Delhi, 110010 India.
Indian J Hematol Blood Transfus. 2018 Apr;34(2):227-232. doi: 10.1007/s12288-017-0913-x. Epub 2018 Feb 3.
There are lot of grey zones in Philadelphia negative chronic myeloproliferative neoplasms (CMPNs) and that's the reason they are in hit list of researchers. Having a spectrum of disorders their diagnosis is very important and especially to differentiate from each other since they overlap with each other in many ways. Diagnosis doesn't start from lab but with clinical phenotype. Clinical phenotype not only able to provide us the diagnosis but also helps in management of the disease per se. When diagnosis comes, the old timer but an evergreen morphology plays an important role which along with the newer generation tool "molecular" helps in differentiating these disorders. Lot of studies have already come up from the world. Indian data has also started coming up. When we say about the Indian data nothing holds more important role than Indian Society of Haematology and Blood Transfusion, ISHBT. This small review will cover all papers with BCR-ABL negative CMPNs which were presented at the annual national conference of the ISHBT (Haematocon 2017) which was conducted at Guwahati. These abstract papers from various reputed institutes and centres will provide a short academic journey towards ongoing research activities at these places and will able to guide us regarding Philadelphia negative CMPNs and also stimulate our brain for some left or conflicted areas.
费城阴性慢性骨髓增殖性肿瘤(CMPNs)存在很多灰色地带,这就是它们成为研究人员重点关注对象的原因。由于这类疾病具有一系列病症,其诊断非常重要,尤其是要将它们彼此区分开来,因为它们在很多方面相互重叠。诊断并非始于实验室检查,而是始于临床表型。临床表型不仅能为我们提供诊断依据,还有助于疾病本身的管理。当进行诊断时,古老但依然重要的形态学发挥着重要作用,它与新一代工具“分子检测”一起有助于区分这些病症。世界各地已经开展了很多研究。印度的数据也开始出现。当我们谈及印度的数据时,没有什么比印度血液学与输血学会(ISHBT)发挥的作用更重要了。这篇简短的综述将涵盖所有在古瓦哈提举行的ISHBT年度全国会议(2017年血液学大会)上发表的关于BCR-ABL阴性CMPNs的论文。这些来自各个知名机构和中心的摘要论文将为我们提供这些地方正在进行的研究活动的简短学术之旅,并能指导我们了解费城阴性CMPNs,还能激发我们对一些存在争议或有待进一步研究的领域的思考。